Dexcom Inc Q1 2022 Earnings Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Robert Justin Marcus - JPMorgan Chase & Co, Research Division - Analyst : Maybe if I can ask, in the U.S. business in fourth quarter, you talked about how you had difficulty accessing primary care channel. First quarter growth in the U.S. came in a little lighter than we would have expected. Maybe just talk about trends there and then conversely talk about some of the early responder trends and feedback you're getting on G7 in Europe?

Question: Mathew Justin Blackman - Stifel, Nicolaus & Company, Incorporated, Research Division - Analyst : You mentioned the growing prescriber base, anything you're willing to share on the size of the prescriber base and in particular, the percent that primary care physicians comprised of that base today versus prior to the sales force expansion? Just anything to help us frame the progress of that newer call point? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. APRIL 28, 2022 / 9:30PM, DXCM.OQ - Q1 2022 Dexcom Inc Earnings Call

Question: Travis Lee Steed - Barclays Bank PLC, Research Division - Analyst : Just wanted a little bit more color on the basal-only population and the conversations that you guys are having with payers. I'm hearing more and more patients in that population getting entrance coverage. So just kind of curious is that what you're seeing on your end as well in conversations with Medicare moving along?